


DAFTAR PUSTAKA

- [1] H. Samant, H. S. Amiri, and G. B. Zibari, "Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management," *Journal of Gastrointestinal Oncology*, vol. 12, pp. S361–S373, 7 2021.
- [2] H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, "Global cancer statistics 2020: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries," *CA: A Cancer Journal for Clinicians*, vol. 71, pp. 209–249, 5 2021.
- [3] K. A. McGlynn, J. L. Petrick, and H. B. El-Serag, "Epidemiology of hepatocellular carcinoma," *Hepatology*, vol. 73, pp. 4–13, 1 2021.
- [4] D. Motola-Kuba, D. Zamora-Valdés, M. Uribe, and N. Méndez-Sánchez, "Hepatocellular carcinoma. an overview," *Annals of Hepatology*, vol. 5, pp. 16–24, 1 2006.
- [5] Z. Chen, H. Xie, M. Hu, T. Huang, Y. Hu, N. Sang, and Y. Zhao, "Recent progress in treatment of hepatocellular carcinoma," *American journal of cancer research*, vol. 10, pp. 2993–3036, 2020.
- [6] M. Reig, A. Forner, J. Rimola, J. Ferrer-Fàbrega, M. Burrel, Ángeles Garcia-Criado, R. K. Kelley, P. R. Galle, V. Mazzaferro, R. Salem, B. Sangro, A. G. Singal, A. Vogel, J. Fuster, C. Ayuso, and J. Bruix, "Bclc strategy for prognosis prediction and treatment recommendation: The 2022 update," *Journal of Hepatology*, vol. 76, pp. 681–693, 3 2022.
- [7] Z.-W. Li, A.-H. Ren, D.-W. Yang, H. Xu, J. Wei, C.-W. Yuan, Z.-C. Wang, and Z.-H. Yang, "Preoperatively predicting early response of hcc to tace using clinical indicators and mri features," *BMC Medical Imaging*, vol. 22, p. 176, 10 2022.
- [8] J. M. Llovet and R. Lencioni, "mrecist for hcc: Performance and novel refinements," *Journal of Hepatology*, vol. 72, pp. 288–306, 2 2020.
- [9] L. Bolondi, A. Burroughs, J.-F. Dufour, P. Galle, V. Mazzaferro, F. Piscaglia, J. Raoul, and B. Sangro, "Heterogeneity of patients with intermediate (bclc b) hepatocellular carcinoma: Proposal for a subclassification to facilitate treatment decisions," *Seminars in Liver Disease*, vol. 32, pp. 348–359, 2 2013.
- [10] J.-J. Yoo, G. E. Chung, J.-H. Lee, J. Y. Nam, Y. Chang, J. M. Lee, D. H. Lee, H. Y. Kim, E. J. Cho, S. J. Yu, Y. J. Kim, and J.-H. Yoon, "Sub-classification of advanced-stage hepatocellular carcinoma: A cohort study including 612 patients treated with sorafenib," *Cancer Research and Treatment*, vol. 50, pp. 366–373, 4 2018.
- [11] X. Zhang, Z. He, Y. Zhang, and J. Kong, "Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using ct radiomics-based machine learning model," *Frontiers in Pharmacology*, vol. 15, 1 2024.
- [12] Z. Dong, Y. Lin, F. Lin, X. Luo, Z. Lin, Y. Zhang, L. Li, Z.-P. Li, S.-T. Feng, H. Cai, and Z. Peng, "Prediction of early treatment response to initial conventional transarterial chemoembolization therapy for hepatocellular carcinoma by machine-learning model based on computed tomography," *Journal of Hepatocellular Carcinoma*, vol. Volume 8, pp. 1473–1484, 11 2021.
- [13] A. Sciarra, M. Ronot, L. D. Tommaso, C. Raschioni, L. Castera, J. Belghiti, P. Bedossa, V. Vilgrain, M. Roncalli, and V. Paradis, "Trip: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma," *Liver International*, vol. 35, pp. 2466–2473, 11 2015.

- [14] J. Balogh, D. Victor, E. H. Asham, S. G. Burroughs, M. Boktour, A. Saharia, X. Li, M. Ghobrial, and H. Monsour, "Hepatocellular carcinoma: a review," *Journal of Hepatocellular Carcinoma*, vol. Volume 3, pp. 41–53, 10 2016.
- [15] J. Wang, K. Qiu, S. Zhou, Y. Gan, K. Jiang, D. Wang, and H. Wang, "Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis," *Annals of Medicine*, vol. 57, 12 2025.
- [16] Álvaro Díaz-González, M. Reig, and J. Bruix, "Treatment of hepatocellular carcinoma," *Digestive Diseases*, vol. 34, pp. 597–602, 2016.
- [17] F. Melchiorre, F. Patella, L. Pescatori, F. Pesapane, E. Fumarola, P. Biondetti, P. Brambillasca, C. Monaco, A. M. Ierardi, G. Franceschelli, and G. Carrafiello, "Deb-tace: A standard review," *Future Oncology*, vol. 14, pp. 2969–2984, 12 2018.
- [18] R. Lencioni and J. Llovet, "Modified recist (mrecist) assessment for hepatocellular carcinoma," *Seminars in Liver Disease*, vol. 30, pp. 052–060, 2 2010.
- [19] S. P. Madani, M. Mirza-Aghazadeh-Attari, A. Mohseni, T. Pawlik, and I. R. Kamel, "Diffuse infiltrative hepatocellular carcinoma: Multimodality imaging manifestations," *Journal of Surgical Oncology*, vol. 127, pp. 385–393, 3 2023.
- [20] V. Kumar, Y. Gu, S. Basu, A. Berglund, S. A. Eschrich, M. B. Schabath, K. Forster, H. J. Aerts, A. Dekker, D. Fenstermacher, D. B. Goldgof, L. O. Hall, P. Lambin, Y. Balagurunathan, R. A. Gatenby, and R. J. Gillies, "Radiomics: the process and the challenges," *Magnetic Resonance Imaging*, vol. 30, pp. 1234–1248, 11 2012.
- [21] S. Kim, J. Shin, D.-Y. Kim, G. H. Choi, M.-J. Kim, and J.-Y. Choi, "Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of postoperative early and late recurrence of single hepatocellular carcinoma," *Clinical Cancer Research*, vol. 25, pp. 3847–3855, 7 2019.
- [22] S. Rizzo, F. Botta, S. Raimondi, D. Origgi, C. Fanciullo, A. G. Morganti, and M. Bellomi, "Radiomics: the facts and the challenges of image analysis," *European Radiology Experimental*, vol. 2, p. 36, 12 2018.
- [23] G. Ge, J. Z. Zhang, and J. Zhang, "The impact of high-order features on performance of radiomics studies in ct non-small cell lung cancer," *Clinical Imaging*, vol. 113, p. 110244, 9 2024.
- [24] X. Ying, "An overview of overfitting and its solutions," *Journal of Physics: Conference Series*, vol. 1168, p. 022022, 2 2019.
- [25] N. Herawati, A. Wijayanti, A. Sutrisno, Nusyirwan, and Misgiyati, "The performance of ridge regression, lasso, and elastic-net in controlling multicollinearity: A simulation and application," *Journal of Modern Applied Statistical Methods*, vol. 23, 1 2024.
- [26] A. W. Moawad, A. Morshid, A. M. Khalaf, M. M. Elmohr, J. D. Hazle, D. Fuentes, M. Badawy, A. O. Kaseb, M. Hassan, A. Mahvash, J. Szklaruk, A. Qayyum, A. Abusaif, W. C. Bennett, T. S. Nolan, B. Camp, and K. M. Elsayes, "Multimodality annotated hepatocellular carcinoma data set including pre-and post-tace with imaging segmentation," *Scientific Data*, vol. 10, p. 33, 1 2023.
- [27] Q. H. Nguyen, H.-B. Ly, L. S. Ho, N. Al-Ansari, H. V. Le, V. Q. Tran, I. Prakash, and B. T. Pham, "Influence of data splitting on performance of machine learning models in prediction of shear strength of soil," *Mathematical Problems in Engineering*, vol. 2021, pp. 1–15, 2 2021.
- [28] T. W. MacFarland and J. M. Yates, *Mann–Whitney U Test*. Springer International Publishing, 2016, pp. 103–132.

- [29] D. Lu, L. Zhou, Z. Zuo, Z. Zhang, X. Zheng, J. Weng, Z. Yu, J. Ji, and J. Xia, "Mri radiomics to predict early treatment response to tace combined with lenvatinib plus a pd-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus," *Journal of Hepatocellular Carcinoma*, vol. Volume 12, pp. 985–998, 5 2025.



UMN
UNIVERSITAS
MULTIMEDIA
NUSANTARA